Binding epitopes for g250 antibody

Abstract

The invention relates to specific amino acid sequences which have been determined to be target epitope for antibodies, in particular, for a G250 antibody.

1 . A vaccine comprising a peptide, said peptide comprising the amino acid sequence LSTAFARV and the amino acid sequence ALGPGREYRAL, wherein the peptide is not carbonic anhydrase IX. 
     
     
         2 . A screening assay for identification of antibodies or binding molecules for CA-IX, comprising
 providing a peptide, said peptide comprising the amino acid sequence LSTAFARV and the amino acid sequence ALGPGREYRAL, wherein the peptide is not carbonic anhydrase IX,   contacting candidate antibodies or binding molecules with said peptide, and   identifying candidate compounds binding to said peptide as G250 antibodies or binding molecules.   
     
     
         3 . A binding molecule for the CA-IX antigen, wherein said binding molecule binds to an isolated synthetic peptide comprising the amino acid sequence LSTAFARV and ALGPGREYRAL, wherein the binding molecules are not the G250 antibody produced by the hybridoma cell line DSM ACC 2526. 
     
     
         4 . The binding molecule of  claim 3 , wherein the binding molecule is an antibody. 
     
     
         5 . Use of the amino acid sequence LSTAFARV and of the amino acid sequence. ALGPGREYRAL as a target. 
     
     
         6 . Use of the amino acid sequence of  claim 5  as a target for therapy. 
     
     
         7 . Use of the amino acid sequence of  claim 5  as target for treatment of cancer. 
     
     
         8 . Use of the amino acid sequence of  claim 5 , wherein the amino acid sequence constitutes a binding site for a therapeutical agent. 
     
     
         9 . Use according to  claim 8 , wherein the therapeutical agent is an antibody or binding molecule capable of binding to a peptide, said peptide comprising the amino acid sequence LSTAFARV and the amino acid sequence ALGPGREYRAL, wherein the peptide is not carbonic anhydrase IX. 
     
     
         10 . Use of an antibody or a binding molecule for therapy, wherein the antibody or binding molecule is bindable to the amino acid sequence LSTAFARV and to the amino acid sequence ALGPGREYRAL.